Stem Cell Research & Therapy · Nov 19, 2026
A straightforward strategy for the isolation of epicardial adipose tissue-derived stromal/stem cells from cardiac patients and subsequent differentiation into cardiomyocyte-like cells
By Heuboeck E, Benedikt P, Huber F et al.
Dysfunctional Epicardial adipose tissue (EAT), a specific beige/brown-like fat depot predominantly present in humans, is associated with coronary artery disease, atrial fibrillation and impaired systolic function. On the molecular level, the pathophysiological role of EAT is incompletely understood because live human EAT samples are restricted and suitable in vitro models recapitulating EAT-specific characteristics are missing. To overcome this limitation, we isolated proliferative Adipose-derived stromal/stem cells (ASCs) from EAT samples of elderly patients undergoing cardiac surgery for subsequent characterization and future disease modeling. EAT-ASCs expressed classical mesenchymal cell-surface markers like CD90 and CD105 in addition to CD31, CD34 and DLK1. Single-cell transcriptomic profiling of EAT-ASCs confirmed their mesenchymal origin and uncovered the expression of various transcription factors involved in cell fate identity including PPARG, GATA4, STAT3 and HIF1A. Differentiation assays demonstrated the ability of EAT-ASCs to develop towards adipogenic-, chondrogenic- and osteogenic lineages. Despite the advanced chronological age of the donors (68.04 -/+ 9 years; n = 34), EAT-ASCs differentiated into cardiomyocyte-like cells (EAT-CMs) simply by using a canonical protocol intended for pluripotent stem cell lines and without the need of lentiviral-mediated reprogramming. EAT-CMs expressed various cardiac markers including cardiac Troponin T (TNNT2) and were responsive to electrical stimulation thus demonstrating the ability to reach a functional level. In conclusion, our study suggests that EAT-ASCs are primed towards the cardiac lineage. Accordingly, our work enables the development of new patient-specific in vitro models to uncover EAT pathophysiology and argues to further investigate EAT-ASCs/EAT-CMs as a novel cell source in regenerative cardiac medicine.